Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a22fa8404e26efe9

Jump to content

// Workers AI · dad joke modeWhat did Beractant say to its friend? "You can surf-act on me.

From Wikipedia, the free encyclopedia

Beractant
Clinical data
Trade namesSurvanta, others
AHFS/Drugs.comMonograph
Routes of
administration
Endotracheal
ATC code
  • None
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
 X markNcheckY (what is this?)  (verify)

Beractant, also known by the trade name of Survanta, is a modified bovine pulmonary surfactant containing bovine lung extract (phospholipids, neutral lipids, fatty acids, and bovine surfactant proteins), to which synthetic DPPC, tripalmitin and palmitic acid are added. The composition provides 25 mg/mL phospholipids, 0.5 to 1.75 mg/mL triglycerides, 1.4 to 3.5 mg/mL free fatty acids, and <1.0 mg/mL total surfactant proteins.[1] As an intratracheal suspension, it can be used for the prevention and treatment of neonatal respiratory distress syndrome.[2] Survanta is manufactured by Abbvie.

Beractant is on the World Health Organization's List of Essential Medicines.[3]

Generic form

[edit]

Beraksurf is generic form of Survanta (Beractant) which is manufacturing by Tekzima.

References

[edit]
  1. Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A, et al. (April 2005). "A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants". Pediatrics. 115 (4): 1018–29. doi:10.1542/peds.2004-2183. PMID 15805380. S2CID 40458323.{{cite journal}}: CS1 maint: overridden setting (link)
  2. Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, Gunkel JH (January 1998). "Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group". The Journal of Pediatrics. 132 (1): 40–7. doi:10.1016/S0022-3476(98)70482-2. PMID 9469998.
  3. World Health Organization (2025). The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. Geneva: World Health Organization. hdl:10665/382243.